Topical ocular administration of DPP-Ⅳ inhibitors: a new approach for treating diabetes-induced retinal neurodegeneration
Rafael Simó
Cristina Hernández
Diabetes and Metabolism Research Unit,Vail d'Hebron Research Institute(VHIR);Department of Medicine,Autonomous University of Barcelona,Barcelona,Spain;Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas(CIBERDEM),Instituto de Salud Carlos Ⅲ(ICSⅢ),Madrid,Spain
摘要：Retinal neurodegeneration plays a significant role in the pathogenesis of diabetic retinopathy(DR), the leading cause of preventable blindness. In fact, the American Diabetes Association has defined DR as a highly specific neurovascular complication (Solomon et al.,2017). Therefore, it is no longer acceptable to consider DR as merely a microvascular complication. In this regard, the term diabetic retinal disease (DRD) has been proposed as a broader term comprising microangiopathy and neurodegeneration. However, there are currently no treatments available that directly target the neurodegenerative changes of DR. This paper will give new insights into the translational research in this field with particular emphasis on glucagon-like peptide 1/dipeptidyl peptidase Ⅳ (GLP-1/DPP-Ⅳ)inhibitors.
机标关键词：administrationinhibitorsneurodapproachdegenerationdiabetesinducedocular
论文发表日期：2024-04-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 713-714 )